Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Dino's Bar & Grill -- Ignore unavailable to you. Want to Upgrade?

To: Goose94 who wrote (79957)	4/29/2020 8:17:40 AM
From: Goose94	Read Replies (2) \| Respond to of 202902

Lexagene Holdings (LXG-V) Industrial Alliance Securities analyst Chelsea Stellick commenced coverage "speculative buy" and $1 share target. Ms. Stellick is the lone wolf covering the stock. Lexagene is developing a fully automated pathogen detection instrument. Ms. Stellick sees "ample upside as the commercial roll-out gains traction." Ms. Stellick says in a note: "LexaGene's instrument, LX2, is currently in its developmental phase with plans for commercialization in H2/F20. The functions of the LX2 are highly relevant in our current environment where timely pathogen detection becomes a vital piece in stopping the spread of disease. We see value in the LX2, particularly in its use in the veterinary diagnostics space, which is expected to be a $29-billion (U.S.) market by 2043. With our conservative assumptions, the LX2 is a scalable, high margin, razor-blade business model which makes it an attractive take-out candidate post successful commercialization.